Potential therapeutic options for COVID-19: an update on current evidence

Z Niknam, A Jafari, A Golchin, F Danesh Pouya… - European journal of …, 2022 - Springer
Abstract SARS-CoV-2, a novel coronavirus, is the agent responsible for the COVID-19
pandemic and is a major public health concern nowadays. The rapid and global spread of …

Innate immunity in protection and pathogenesis during coronavirus infections and COVID-19

RKS Malireddi, BR Sharma… - Annual Review of …, 2024 - annualreviews.org
The COVID-19 pandemic was caused by the recently emerged β-coronavirus SARS-CoV-2.
SARS-CoV-2 has had a catastrophic impact, resulting in nearly 7 million fatalities worldwide …

An update of anti-viral treatment of COVID-19.

S ŞİMŞEK YAVUZ… - Turkish journal of …, 2021 - search.ebscohost.com
Background/aim: Currently there is not an effective antiviral treatment for COVID-19, but a
large number of drugs have been evaluated since the beginning of the pandemic, and many …

The role of type I interferon in the treatment of COVID‐19

F Sodeifian, M Nikfarjam, N Kian… - Journal of medical …, 2022 - Wiley Online Library
Although significant research has been done to find effective drugs against coronavirus
disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 …

[HTML][HTML] JAK inhibitor blocks COVID-19 cytokine–induced JAK/STAT/APOL1 signaling in glomerular cells and podocytopathy in human kidney organoids

SE Nystrom, G Li, S Datta, KL Soldano, D Silas… - JCI insight, 2022 - ncbi.nlm.nih.gov
COVID-19 infection causes collapse of glomerular capillaries and loss of podocytes,
culminating in a severe kidney disease called COVID-19–associated nephropathy …

A comprehensive review on the efficacy of several pharmacologic agents for the treatment of COVID-19

F Haddad, G Dokmak, R Karaman - Life, 2022 - mdpi.com
Simple Summary Treatments for coronavirus disease-2019 (COVID-19) have utilized a
variety of medications, including antivirals, immunomodulators, and other therapeutics such …

The value of Interferon β in multiple sclerosis and novel opportunities for its anti-viral activity: a narrative literature review

G Bellucci, A Albanese, C Rizzi, V Rinaldi… - Frontiers in …, 2023 - frontiersin.org
Interferon-beta (IFN-β) for Multiple Sclerosis (MS) is turning 30. The COVID-19 pandemic
rejuvenated the interest in interferon biology in health and disease, opening translational …

[HTML][HTML] Effects of interferon beta in COVID-19 adult patients: systematic review

JP Sosa, MMF Caceres, JR Comptis… - Infection & …, 2021 - ncbi.nlm.nih.gov
Background The high rate of transmission and infection of coronavirus disease 2019
(COVID-19) is a public health emergency of major epidemiological concern. No definitive …

Interferon‐alpha position in combating with COVID‐19: A systematic review

A Nakhlband, A Fakhari, H Azizi - Journal of medical virology, 2021 - Wiley Online Library
The newborn coronaivus disease 2019 (COVID‐19) pandemic has become the foremost
concern of health system worldwide. Interferon typeI (IFN‐I) are among the well‐known …

Induction of innate immune response by TLR3 agonist protects mice against SARS-CoV-2 infection

H Tamir, S Melamed, N Erez, B Politi… - Viruses, 2022 - mdpi.com
SARS-CoV-2, a member of the coronavirus family, is the causative agent of the COVID-19
pandemic. Currently, there is still an urgent need in developing an efficient therapeutic …